Aurelija Abraityte

Aurelija Abraityte

Auto-generated profile, based on publicly available information

Aurelija Abraityte

Research Institute of Internal Medicine, Oslo University Hospital, Rikshospitalet; Postboks 4950 Nydalen, 0424, Oslo, Norway.

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 March 2017 in Journal of Molecular Medicine
Verified
Journal Article
Closed access
PDF file
AAAurelija Abraityte
Aurelija Abraityte
LVLeif E. Vinge
Leif E. Vinge
EAErik T. Askevold
Erik T. Askevold
TLTove Lekva
Tove Lekva
AMAnnika E. Michelsen
Annika E. Michelsen
TUThor Ueland
Thor Ueland

28 August 2015 in Arthritis Research & Therapy
Verified
Journal Article
Open access
PDF file
SRSilje Reiseter
Silje Reiseter
ØMØyvind Molberg
Øyvind Molberg
RGRagnar Gunnarsson
Ragnar Gunnarsson
MLMay Brit Lund
May Brit Lund
TATrond Mogens Aalokken
Trond Mogens Aalokken
AHAnna-Maria Hoffmann-Vold
Anna-Maria Hoffmann-Vold
Systemic sclerosis (SSc) and mixed connective tissue disease (MCTD) are chronic immune-mediated disorders complicated by vascular organ damage. The aim of this study was to examine the serum levels of the markers of neoangiogenesis: endostatin and vascular endothelial growth factor (VEGF), in our unselected cohorts of SSc and MCTD. Sera of SSc patients (N = 298) and MCTD patients (N = 162) from two longitudinal Norwegian cohorts were included. Blood donors were included as controls (N = 100). Circulating VEGF and endostatin were analyzed by enzyme immunoassay. Mean endostatin levels were increased in SSc patients 93.7 (37) ng/ml (P < .001) and MCTD patients 83.2 (25) ng/ml (P < .001) compared to controls 65.1 (12) ng/ml. Median VEGF levels were elevated in SSc patients 209.0 (202) pg/ml compared to MCTD patients 181.3 (175) pg/ml (P = .017) and controls 150.0 (145) pg/ml (P < .001). Multivariable analysis of SSc subsets showed that pulmonary arterial hypertension (coefficient 15.7, 95 % CI: 2.2–29.2, P = .023) and scleroderma renal crisis (coefficient 77.6, 95 % CI: 59.3–100.0, P < .001) were associated with elevated endostatin levels. Multivariable analyses of MCTD subsets showed that digital ulcers were associated with elevated endostatin levels (coefficient 10.5, 95 % CI: 3.2–17.8, P = .005). The risk of death increased by 1.6 per SD endostatin increase (95 % CI: 1.2–2.1, P = .001) in the SSc cohort and by 1.6 per SD endostatin increase (95 % CI: 1.0–2.4, P = .041) in the MCTD cohort after adjustments to known risk factors. Endostatin levels were elevated in patients with SSc and MCTD, particularly SSc patients with pulmonary arterial hypertension and scleroderma renal crisis, and MCTD patients with digital ulcers. Elevated endostatin levels were also associated with increased all-cause mortality during follow-up in both groups of patients. We propose that endostatin might indicate the degree of vascular injury in SSc and MCTD patients.


1 February 2015 in International Journal of Cardiology
Verified
Journal Article
Closed access
AAAurelija Abraityte
Aurelija Abraityte
LGLars Gullestad
Lars Gullestad
EAErik Tandberg Askevold
Erik Tandberg Askevold
SNStåle Nymo
Ståle Nymo
CDChristen P. Dahl
Christen P. Dahl
TUThor Ueland
Thor Ueland